Clostridium difficile infection: new developments in epidemiology and pathogenesis
The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Abstract
Clostridium difficile is now considered to be one of the most important causes of health care-associated infections. C. difficile infections are also emerging in the community and in animals used for food, and are no longer viewed simply as unpleasant complications that follow antibiotic therapy. Since 2001, the prevalence and severity of C. difficile infection has increased significantly, which has led to increased research interest and the discovery of new virulence factors, and has expanded and focused the development of new treatment and prevention regimens. This Review summarizes the recent epidemiological changes in C. difficile infection, our current knowledge of C. difficile virulence factors and the clinical outcomes of C. difficile infection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, studies have demonstrated that patients suffering from recurrent CDI are deficient in phyla of bacteria normally dominant in the colon6,45 (Figure 1).”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [45]
Citations
Cites
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361 · cited 1×
“It is becoming evident from 16S ribosomal RNA sequencing that disruption of the gut microbiota following antibiotic treatment is much greater than was previously realize”
BackgroundAn Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Interventions to improve antibiotic prescribing practices for hospital inpatients
Davey, P., Brown, E., Charani, E., Fenelon, L., Gould, I. M., Holmes, A., Ramsay, C. R., Wiffen, P. J., & Wilcox, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003543.pub3 · Cited by 1,864
Nosocomial Acquisition of Clostridium difficile Infection
McFarland, L. V., Mulligan, M. E., Kwok, R. Y. Y., & Stamm, W. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198901263200402 · Cited by 1,326
Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128
Glucosylation of Rho proteins by Clostridium difficile toxin B
Just, I., Selzer, J., Wilm, M., Eichel-Streiber, C. V., Mann, M., & Aktories, K. (1995) · Nature · doi:10.1038/375500a0 · Cited by 1,032
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Pepin, J., Saheb, N., Coulombe, M.-A., Alary, M.-E., Corriveau, M.-P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496986 · Cited by 995
Research works printed but not linked: 5
- Summary points on quarterly (October to December. 2008) and financial year (2007/08) acute Trust Clostridium difficile data. Key points: analyses of quarterly mandatory Clostridium difficile surveillance data. Health Protection Agency [online] , (2008).
- Thompson, A. et al. in Ninth Biennial Congress of the Anaerobe Society of Americas. PII-14 (Long Beach, California, 2008).
- Angulo, F. et al. in Second International Clostridium difficile Symposium. P5 (Maribor, Slovenia, 2007).
- Louie, T. et al. in The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. K-425a (Chicago, Illinois, 2007).
- Merrigan, M. M., Gerding, D. N. & Vedantam, G. in Eighth Biennial Conference of the Anaerobe Society of America. PI-12 (Boise, Idaho, 2006).
Cited by
Items 201–300 of 999
de Bruyn, G., Saleh, J., Workman, D., Pollak, R. A., Elinoff, V., Fraser, N. J., Lefebvre, G., Martens, M. G., Mills, R. E., Nathan, R., et al. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.03.028 · Cited by 95
Prevalence and diversity of Clostridium difficile strains in infants
Rousseau, C., Lemée, L., Le Monnier, A., Poilane, I., Pons, J.-L., & Collignon, A. (2011) · Journal of Medical Microbiology · doi:10.1099/jmm.0.029736-0 · Cited by 94
“This leads to asymptomatic carriage or a wide spectrum of diseases, ranging from mild diarrhoea to severe pseudomembranous colitis (Rupnik et al., 2009).”
BackgroundNisin is an effective inhibitor of Clostridium difficile vegetative cells and spore germination
Lay, C. L., Dridi, L., Bergeron, M. G., Ouellette, M., & Fliss, I. (2016) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000202 · Cited by 94
“difficile may produce a wide spectrum of outcomes that range from asymptomatic colonization to acute diarrhoea and pseudomembranous colitis, which can result in colonic perforation and death if untreated (Kelly & LaMont, 2008; Rupnik et al., 2009; Stanley et al., 2013).”
BackgroundRecurrent Clostridium difficile infection: From colonization to cure
Shields, K., Araujo-Castillo, R. V., Theethira, T. G., Alonso, C. D., & Kelly, C. P. (2015) · Anaerobe · doi:10.1016/j.anaerobe.2015.04.012 · Cited by 93
Monteiro, C. R. A. V., do Carmo, M. S., de Melo, B. O., Alves, M. S., dos Santos, C. I., Monteiro, S. G., Bomfim, M. R. Q., Fernandes, E. S., & Monteiro‐Neto, V. (2019) · Nutrients · doi:10.3390/nu11020448 · Cited by 111
“For example, Clostridium difficile is described as one of the leading causes of diarrhea and colitis associated with antibiotic use, with detection frequency ranging from 13% to 28% [9,18].”
BackgroundMenendez, A., Willing, B. P., Montero, M., Wlodarska, M., So, C. C., Bhinder, G., Vallance, B. A., & Finlay, B. B. (2013) · Journal of Innate Immunity · doi:10.1159/000341630 · Cited by 93
Clostridium difficileIsolates Resistant to Fluoroquinolones in Italy: Emergence of PCR Ribotype 018
Spigaglia, P., Barbanti, F., Dionisi, A. M., & Mastrantonio, P. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02482-09 · Cited by 93
“The risk of CDI appears to be greater with certain antimicrobial agents and increases if strains are resistant to administered antimicrobials (30).”
BackgroundA Chimeric Toxin Vaccine Protects against Primary and Recurrent Clostridium difficile Infection
Wang, H., Sun, X., Zhang, Y., Li, S., Chen, K., Shi, L., Nie, W., Kumar, R., Tzipori, S. R., Wang, J., et al. (2012) · Infection and Immunity · doi:10.1128/iai.00215-12 · Cited by 94
“Clostridium difficile is the most common cause of nosocomial antibiotic-associated diarrhea and is the etiologic agent of pseudomembranous colitis (8, 27, 45).”
BackgroundStructure of the full-length Clostridium difficile toxin B
Chen, P., Lam, K. H., Liu, Z., Mindlin, F. A., Chen, B., Gutierrez, C. B., Huang, L., Zhang, Y., Hamza, T., Feng, H., et al. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0268-0 · Cited by 102
Steele, J., Chen, K., Sun, X., Zhang, Y., Wang, H., Tzipori, S. R., & Feng, H. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir748 · Cited by 96
“In the United States, some 500 000 cases of CDI, with approximately 15 000–20 000 deaths, are reported annually [29, 30].”
BackgroundWarriner, K., Xu, C., Habash, M., Sultan, S., & Weese, S. J. (2016) · Journal of Applied Microbiology · doi:10.1111/jam.13338 · Cited by 129
“difficile into toxinotypes of which there are currently 31 identified (Rupnik et al. 2009).”
BackgroundMethodSurviving Between Hosts: Sporulation and Transmission
Swick, M. C., Koehler, T. M., & Driks, A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.vmbf-0029-2015 · Cited by 110
“anthracis, for which sporulation within the host has not be observed (35, 36).”
BackgroundAn ecological framework to understand the efficacy of fecal microbiota transplantation
Xiao, Y., Angulo, M. T., Lao, S., Weiss, S. T., & Liu, Y.-Y. (2020) · Nature Communications · doi:10.1038/s41467-020-17180-x · Cited by 89
Gastrointestinal Organoids: Understanding the Molecular Basis of the Host–Microbe Interface
Hill, D. R., & Spence, J. R. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.11.007 · Cited by 88
Roth, K. D. R., Wenzel, E. V., Ruschig, M., Steinke, S., Langreder, N., Heine, P. A., Schneider, K.-T., Ballmann, R., Fühner, V., Kuhn, P., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.697876 · Cited by 102
“Due to increasing CDAD case numbers and epidemic outbreaks (Rupnik et al., 2009; Depestel and Aronoff, 2013), these two toxins were targets of several antibody-generationcampaigns (Babcock et al.”
BackgroundRohokale, R., & Guo, Z. (2023) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00559 · Cited by 95
Knight, D. R., Squire, M. M., & Riley, T. V. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.03032-14 · Cited by 91
“RT078 is being found increasingly in cases of community-associated CDI (CA-CDI) outside Australia (1), suggesting that livestock, via the environment and/or food, are a reservoir for disease-causing strains in humans (18, 19).”
BackgroundSun, X., & Hirota, S. A. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.09.005 · Cited by 91
“Antibiotic exposure is the most significant risk factor for CDI [2, 6].”
BackgroundTeng, C., Reveles, K. R., Obodozie-Ofoegbu, O. O., & Frei, C. R. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.30739 · Cited by 87
Mansfield, M. J., Tremblay, B. J.-M., Zeng, J., Wei, X., Hodgins, H., Worley, J. N., Bry, L., Dong, M., & Doxey, A. C. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009181 · Cited by 91
Pantaleon, V., Soavelomandroso, A. P., Bouttier, S., Briandet, R., Roxas, B. P., Chu, M., Collignon, A., Janoir, C., Vedantam, G., & Candela, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124971 · Cited by 87
Barra-Carrasco, J., Olguín-Araneda, V., Plaza-Garrido, Á., Miranda-Cárdenas, C., Cofré-Araneda, G., Pizarro‐Guajardo, M., Sarker, M. R., & Paredes‐Sabja, D. (2013) · Journal of Bacteriology · doi:10.1128/jb.00369-13 · Cited by 110
“Two toxins, the TcdA enterotoxin and the TcdB cytotoxin (2), are responsible for the clinical manifestations of Clostridium difficile infections (CDI), which include a massive inflammatory response, recruitment of phagocytic cells, and pseudomembrane formation (2).”
BackgroundTherapeutic transplantation of the distal gut microbiota
Khoruts, A., & Sadowsky, M. J. (2010) · Mucosal Immunology · doi:10.1038/mi.2010.79 · Cited by 97
Oka, K., Osaki, T., Hanawa, T., Kurata, S., Okazaki, M., Manzoku, T., Takahashi, M., Tanaka, M., Taguchi, H., Watanabe, T., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05588-11 · Cited by 91
“difficile, strain BI/NAP1/027, which produces a binary toxin, have been reported in North America and Europe (28, 35).”
BackgroundInfluentialde Bruyn, G., Gordon, D., Steiner, T. S., Tambyah, P. A., Cosgrove, C., Martens, M. G., Bassily, E. L., Chan, E.-S., Patel, D. M., Chen, J., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30331-5 · Cited by 89
Risk Estimation for Recurrent Clostridium difficile Infection Based on Clinical Factors
D'Agostino, R. B., Collins, S. H., Pencina, K. M., Kean, Y., & Gorbach, S. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu107 · Cited by 85
“Recurrence of CDI is associated with substantial morbidity and mortality and increased medical costs [16–20].”
BackgroundShen, E., Zhu, K., Li, D., Pan, Z., Luo, Y., Bian, Q., He, L., Song, X., Zhen, Y., Jin, D., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-1078-y · Cited by 84
Phage Therapy in Gastrointestinal Diseases
Gutiérrez, B., & Domingo‐Calap, P. (2020) · Microorganisms · doi:10.3390/microorganisms8091420 · Cited by 99
“PaLoc is believed to have its origin in an ancient phage, as it shares certain characteristics with phages, particularly the tcdE gene, which encodes a phage-like sequence involved in the secretion of the toxins.”
BackgroundProtein composition of the outermost exosporium-like layer of Clostridium difficile 630 spores
Díaz-González, F., Milano, M., Olguín-Araneda, V., Pizarro-Cerda, J., Castro-Córdova, P., Tzeng, S., Maier, C. S., Sarker, M. R., & Paredes‐Sabja, D. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.03.035 · Cited by 87
Marozsan, A. J., Ma, D., Nagashima, K. A., Kennedy, B. J., Kang, Y., Arrigale, R. R., Donovan, G. P., Magargal, W. W., Maddon, P. J., & Olson, W. C. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis416 · Cited by 84
Analysis of Bacterial Communities during Clostridium difficile Infection in the Mouse
Semenyuk, E. G., Poroyko, V. A., Johnston, P. F., Jones-Burrage, S. E., Knight, K. L., Gerding, D. N., & Driks, A. (2015) · Infection and Immunity · doi:10.1128/iai.00145-15 · Cited by 92
“difficile spores, spore germination in the gastrointestinal (GI) tract, and then colonization of the large intestine (1).”
BackgroundClostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms
Banawas, S. (2018) · BioMed Research International · doi:10.1155/2018/8414257 · Cited by 98
“The clinical symptoms of CDI range from mild to severe diarrhea, which can lead to fulminant colitis, toxic megacolon, bowel perforation, sepsis, and ultimately death [5].”
BackgroundMikamo, H., Tateda, K., Yanagihara, K., Kusachi, S., Takesue, Y., Miki, T., Oizumi, Y., Gamo, K., Hashimoto, A., Toyoshima, J., et al. (2018) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2018.05.010 · Cited by 90
Characterization of the collagen-like exosporium protein, BclA1, of Clostridium difficile spores
Pizarro‐Guajardo, M., Olguín-Araneda, V., Barra, J., Brito-Silva, C., Sarker, M. R., & Paredes‐Sabja, D. (2013) · Anaerobe · doi:10.1016/j.anaerobe.2013.11.003 · Cited by 84
“Clostridium difficile is a nosocomial anaerobic pathogen, responsible for w20% of antibiotic associated diarrhea [1,2].”
BackgroundClostridium difficilein foods and animals: history and measures to reduce exposure
Rodriguez‐Palacios, A., Borgmann, S., Kline, T. R., & LeJeune, J. T. (2013) · Animal Health Research Reviews · doi:10.1017/s1466252312000229 · Cited by 109
“Low antibody titers effective against the C. difficile toxins (Wilcox, 2004), and disrupted intestinal flora due to antimicrobials (Rupnik et al., 2009) are among the factors that enhance susceptibility to reinfections.”
BackgroundValdés-Varela, L., Hernández‐Barranco, A. M., Ruas‐Madiedo, P., & Gueimonde, M. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00738 · Cited by 97
Locher, H. H., Caspers, P., Bruyère, T., Schroeder, S., Pfaff, P., Knezevic, A., Keck, W., & Ritz, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01831-13 · Cited by 85
“difficile-associated diarrhea) is a major health care problem with significant morbidity and mortality, especially in elderly hospitalized patients (1).”
BackgroundJafari, N. V., Kuehne, S. A., Bryant, C. E., Elawad, M., Wren, B. W., Minton, N. P., Allan, E., & Bajaj‐Elliott, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069846 · Cited by 81
“Currently CDI is considered the leading cause of hospital and community-acquired antibiotic-associated diarrhoea in the western world [3–5].”
BackgroundAnanthakrishnan, A. N., Perez, R. G., Gainer, V. S., Cai, T., Churchill, S. E., Kohane, I. S., Plenge, R. M., & Murphy, S. N. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05022.x · Cited by 81
Effect of Age on Treatment Outcomes in Clostridium difficile Infection
Louie, T. J., Miller, M. A., Crook, D. W., Lentnek, A., Bernard, L., High, K. P., Shue, Y., & Gorbach, S. L. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12090 · Cited by 80
Sirard, S., Valiquette, L., & Fortier, L. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05053-11 · Cited by 80
“difficile infection (CDI) varies in severity, with patients presenting with symptoms ranging from very mild diarrhea to fulminant colitis with complications such as toxic megacolon, bowel perforation, sepsis, and death (33).”
BackgroundVinner, G. K., Vladisavljević, G. T., Clokie, M. R. J., & Malik, D. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186239 · Cited by 83
Bloomfield, L., & Riley, T. V. (2016) · Infectious Diseases and Therapy · doi:10.1007/s40121-016-0117-y · Cited by 95
“[26])”
BackgroundRomano, V., Pasquale, V., Krovacek, K., Mauri, F., Demarta, A., & Dumontet, S. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.01379-12 · Cited by 78
“Toxins are considered the main virulence factors of this microorganism (38).”
BackgroundBalassiano, I. T., Yates, E. A., Domingues, R. M. C. P., & Ferreira, E. D. O. (2011) · Journal of Medical Microbiology · doi:10.1099/jmm.0.037077-0 · Cited by 78
“…Spain; in Asia, including Japan, Korea and Hong Kong; and in Australia, where a few cases have been reported (Kato et al., 2007; Kuijper et al., 2007; Bacci et al., 2009; O’Connor et al., 2009; Riley et al., 2009; Rupnik et al., 2009; Tae et al., 2009; Baldan et al., 2010; Freeman et al., 2010).”
BackgroundInfluentialSeekatz, A. M., Safdar, N., & Khanna, S. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221134396 · Cited by 101
Diagnosis and Management of Infectious Complications in Critically Ill Patients with Cancer
Thirumala, R., Ramaswamy, M., & Chawla, S. (2009) · Critical Care Clinics · doi:10.1016/j.ccc.2009.09.007 · Cited by 80
“It is characterized by fluoroquinolone resistance and is associated with increased toxin production causing a higher mortality rate than other strains.(117,118) Clinically significant strains”
BackgroundBloomfield, M. G., Sherwin, J. C., & Gkrania‐Klotsas, E. (2012) · Journal of Hospital Infection · doi:10.1016/j.jhin.2012.05.008 · Cited by 77
Fidaxomicin inhibits toxin production in Clostridium difficile
Babakhani, F., Bouillaut, L., Sears, P. S., Sims, C., Gómez, A. S. A., & Sonenshein, A. L. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks450 · Cited by 87
“Clostridium difficile is a spore-forming anaerobic bacterium that has become a major cause of infectious diarrhea in healthcare settings and in the community [1].”
BackgroundDabrera, G., Zhao, H., Andrews, N. J., Begum, F., Green, H. K., Ellis, J., Elias, K. M., Donati, M., Zambon, M. C. F. A., & Pebody, R. G. (2014) · Eurosurveillance · doi:10.2807/1560-7917.es2014.19.45.20959 · Cited by 89
Louie, T., Nord, C. E., Talbot, G. H., Wilcox, M. H., Gerding, D. N., Buitrago, M. I., Kracker, H., Charef, P., & Cornely, O. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00504-15 · Cited by 76
“difficile BI/NAP1/027 strain, first reported in 2005 (1, 4).”
BackgroundIL-17–producing γδ T cells protect against Clostridium difficile infection
Chen, Y.-S., Chen, I.-B. D., Pham, G. H., Shao, T., Bangar, H., Way, S. S., & Haslam, D. B. (2020) · Journal of Clinical Investigation · doi:10.1172/jci127242 · Cited by 78
“difficile, toxins A and B (TcdA and TcdB), on the intestinal epithelium (15).”
BackgroundKufelnicka, A. M., & Kirn, T. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir201 · Cited by 75
“to mount a sufficient anamnestic immune response and ranges from mild diarrhea to severe, debilitating complications [4].”
BackgroundA review of Clostridioides [Clostridium] difficile occurrence through the food chain
Candel-Pérez, C., Ros, G., & Martínez‐Graciá, C. (2018) · Food Microbiology · doi:10.1016/j.fm.2018.08.012 · Cited by 87
Willing, S. E., Candela, T., Shaw, H. A., Seager, Z., Mesnage, S., Fagan, R. P., & Fairweather, N. F. (2015) · Molecular Microbiology · doi:10.1111/mmi.12958 · Cited by 75
“Clostridium difficile is a Gram-positive spore-forming pathogen and is a leading cause of infectious diarrhoea worldwide (Rupnik et al., 2009; Cairns et al., 2012).”
BackgroundClostridium difficile Genotypes in Piglet Populations in Germany
Schneeberg, A., Neubauer, H., Schmoock, G., Baier, S., Harlizius, J., Nienhoff, H., Brase, K., Zimmermann, S., & Seyboldt, C. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01440-13 · Cited by 75
“In recent years, CDI has also been increasingly recognized as a cause of community-acquired diarrhea (1, 2).”
BackgroundHudson, L. E., Anderson, S. E., Corbett, A. H., & Lamb, T. J. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00049-16 · Cited by 88
“Both CDI and UC are serious GI diseases that are increasing in prevalence (22, 23).”
BackgroundGuidelines on Implementing Antimicrobial Stewardship Programs in Korea
Yoon, Y. K., Kwon, K. T., Jeong, S. J., Moon, C., Kim, B., Kiem, S., Kim, H.-S., Heo, E., Kim, S., Korean Society for Antimicrobial Therapy, et al. (2021) · Infection and Chemotherapy · doi:10.3947/ic.2021.0098 · Cited by 86
“C. difficile is an enteropathogen that colonizes the intestine after antimicrobial treatment [194].”
Function of the CRISPR-Cas System of the Human Pathogen Clostridium difficile
Boudry, P., Semenova, E., Monot, M., Datsenko, K. A., Lopatina, A., Sekulović, O., Ospina-Bedoya, M., Fortier, L., Severinov, K., Dupuy, B., et al. (2015) · mBio · doi:10.1128/mbio.01112-15 · Cited by 94
“difficile from preexisting or acquired spores (4, 5).”
BackgroundRosenbusch, K. E., Bakker, D., Kuijper, E. J., & Smits, W. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048608 · Cited by 94
“difficile infection (CDI) (for recent reviews see [24,25]).”
BackgroundVaccine Production to Protect Animals Against Pathogenic Clostridia
Zaragoza, N. E., Orellana, C. A., Moonen, G., Moutafis, G., & Marcellin, E. (2019) · Toxins · doi:10.3390/toxins11090525 · Cited by 73
“difficle (arguably a distinct genus) infections [16].”
Dembek, M., Stabler, R. A., Witney, A. A., Wren, B. W., & Fairweather, N. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064011 · Cited by 88
“Clostridium difficile is a Gram-positive, anaerobic bacterium and a leading cause of antibiotic-associated diarrhoea in industrialised countries [1].”
BackgroundUnger, M., Eichhoff, A. M., Schumacher, L., Strysio, M., Menzel, S., Schwan, C., Alzogaray, V., Zylberman, V., Séman, M., Brandner, J. M., et al. (2015) · Scientific Reports · doi:10.1038/srep07850 · Cited by 78
Kumar, N., Miyajima, F., He, M., Roberts, P., Swale, A., Ellison, L., Pickard, D., Smith, G., Molyneux, R., Gordon Dougan, B., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ1031 · Cited by 71
“that confound standard infection control measures [5].”
de Gunzburg, J., Ducher, A., Modess, C., Wegner, D., Oswald, S., Dressman, J., Augustin, V., Feger, C., Andremont, A., Weitschies, W., et al. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.359 · Cited by 72
“Intestinal side effects of antibiotic treatments include the emergence and spread of resistant bacteria as well as the occurrence of Clostridium difficile-associated diarrhea, both of which are first line public health concerns.(1,2) A key strategy proposed to minimize these side effects is to prevent the local action…”
BackgroundHigh Prevalence of Clostridium difficile Colonization among Nursing Home Residents in Hesse, Germany
Arvand, M., Moser, V., Schwehn, C., Bettge-Weller, G., Hensgens, M. P., & Kuijper, E. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030183 · Cited by 71
“difficile can only colonize the gut if the normal intestinal flora is disturbed or absent [1].”
BackgroundDefining an allosteric circuit in the cysteine protease domain of Clostridium difficile toxins
Shen, A., Lupardus, P. J., Gersch, M., Puri, A. W., Albrow, V. E., García, K. C., & Bogyo, M. S. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1990 · Cited by 71
“difficile are the primary virulence factors of this important and emergent nosocomial pathoge”
BackgroundKint, N., Janoir, C., Monot, M., Hoys, S., Soutourina, O., Dupuy, B., & Martin‐Verstraete, I. (2017) · Environmental Microbiology · doi:10.1111/1462-2920.13696 · Cited by 70
Recent Drug-Repurposing-Driven Advances in the Discovery of Novel Antibiotics
Konreddy, A. K., Rani, G. U., Lee, K., & Choi, Y. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666180706101404 · Cited by 71
Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole
Chong, P. M., Lynch, T., McCorrister, S. J., Kibsey, P., Miller, M., Gravel, D., Westmacott, G., Mulvey, M. R., & (CNISP), T. C. N. I. S. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0082622 · Cited by 79
Calderón-Romero, P., Castro-Córdova, P., Reyes-Ramírez, R., Cespedes, M. M., Guerrero-Araya, E., Pizarro‐Guajardo, M., Olguín-Araneda, V., Gil, F., & Paredes‐Sabja, D. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007199 · Cited by 70
Gut Microbiota Patterns Associated with Colonization of Different Clostridium difficile Ribotypes
Skraban, J., Dzeroski, S., Zenko, B., Mongus, D., Gangl, S., & Rupnik, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058005 · Cited by 70
Ivarsson, M. E., Leroux, J., & Castagner, B. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201104384 · Cited by 79
Stone, N. E., Sidak‐Loftis, L. C., Sahl, J. W., Vazquez, A. J., Wiggins, K., Gillece, J. D., Hicks, N. D., Schupp, J. M., Busch, J. D., Keim, P., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164504 · Cited by 70
Occurrence of toxigenic Clostridium difficile in edible bivalve molluscs
Pasquale, V., Romano, V., Rupnik, M., Capuano, F., Bove, D., Aliberti, F., Krovacek, K., & Dumontet, S. (2012) · Food Microbiology · doi:10.1016/j.fm.2012.03.001 · Cited by 69
Identification of a Novel Lipoprotein Regulator of Clostridium difficile Spore Germination
Fimlaid, K. A., Jensen, O., Donnelly, M. L., Francis, M. B., Sorg, J. A., & Shen, A. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005239 · Cited by 79
Synthetic Polymers Active against Clostridium difficile Vegetative Cell Growth and Spore Outgrowth
Liu, R., Suárez, J. M., Weisblum, B., Gellman, S. H., & McBride, S. M. (2014) · Journal of the American Chemical Society · doi:10.1021/ja506798e · Cited by 73
Hensbergen, P. J., Klychnikov, O. I., Bakker, D., van Winden, V. J. C., Ras, N., Kemp, A. C., Cordfunke, R. A., Dragan, I., Deelder, A. M., Kuijper, E. J., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.034728 · Cited by 68
“(IgA2(1)) (30), the IgA2 subclass is resistant to other bacterial”
BackgroundClostridioides difficile phage biology and application
Heuler, J., Fortier, L., & Sun, X. (2021) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab012 · Cited by 79
Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile
Babakhani, F., Gomez, A., Robert, N., & Sears, P. S. (2011) · Journal of Medical Microbiology · doi:10.1099/jmm.0.029470-0 · Cited by 68
“Current standard therapies are inadequate, the response rate to metronidazole has declined and there is a high rate of recurrence of infection following treatment with either metronidazole or vancomycin (Miller, 2010; Rupnik et al., 2009).”
BackgroundInfluentialContribution of Spores to the Ability of Clostridium difficile To Adhere to Surfaces
Joshi, L. T., Phillips, D. S., Williams, C. F., Alyousef, A. A., & Baillie, L. W. J. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.01862-12 · Cited by 86
“The subsequent increase in vascular permeability leads to the formation of pseudomembranes composed of neutrophils, fibrin, mucosa, blood, and cellular debris (28, 32).”
BackgroundDiet and Gut Microbiota in Health and Disease
Shen, T. D. (2017) · Nestlé Nutrition Institute Workshop series · doi:10.1159/000455220 · Cited by 82
Puri, A. W., Lupardus, P. J., Deu, E., Albrow, V. E., García, K. C., Bogyo, M. S., & Shen, A. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.09.011 · Cited by 67
“Because of its natural antibiotic resistance, there has been increased focus on targeting the glucosylating toxins TcdA and TcdB for direct therapeutic intervention because they are the primary mediators of C. difficile pathogenesis (Halsey, 2008; Kelly and LaMont, 2008; Rupnik et al., 2009 ).”
Bai, X., Fu, R., Duan, Z., Wang, P., Zhu, C., & Fan, D. (2021) · Food Research International · doi:10.1016/j.foodres.2021.110465 · Cited by 67
Walter, B. M., Cartman, S. T., Minton, N. P., Butala, M., & Rupnik, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144763 · Cited by 78
“difficile is a nosocomial, Gram-positive, anaerobic pathogen which causes a range of intestinal diseases associated with antibiotic treatment [11].”
Backgrounddi Masi, A., Leboffe, L., Polticelli, F., Tonon, F., Zennaro, C., Caterino, M., Stano, P., Fischer, S., Hägele, M., Müller, M., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy338 · Cited by 71
The Infectious Disease Ontology in the age of COVID-19
Babcock, S., Beverley, J. R., Cowell, L. G., & Smith, B. (2021) · Journal of Biomedical Semantics · doi:10.1186/s13326-021-00245-1 · Cited by 85
“A single disease may manifest a variety of symptoms, making it difficult to distinguish the disease definitionally from other diseases involving the same anatomical system [13].”
BackgroundClostridioides difficile LuxS mediates inter-bacterial interactions within biofilms
Slater, R. T., Frost, L. R., Jossi, S. E., Millard, A. D., & Unnikrishnan, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-46143-6 · Cited by 74
“CDI is primarily a hospital-acquired infection with the elderly being at highest risk [6] and has been associated with the”
BackgroundWang, S., Shen, A., Setlow, P., & Li, Y.-Q. (2015) · Journal of Bacteriology · doi:10.1128/jb.00200-15 · Cited by 73
Roles of Cysteine Proteases Cwp84 and Cwp13 in Biogenesis of the Cell Wall of Clostridium difficile
de la Riva, L., Willing, S. E., Tate, E. W., & Fairweather, N. F. (2011) · Journal of Bacteriology · doi:10.1128/jb.00248-11 · Cited by 92
“Clinical symptoms of disease range from mild or severe diarrhea to serious inflammatory conditions including pseudomembranous colitis (34).”
BackgroundBoonma, P., Spinler, J. K., Venable, S. F., Versalovic, J., & Tumwasorn, S. (2014) · BMC Microbiology · doi:10.1186/1471-2180-14-177 · Cited by 66
“The disruption of tight junctions is thought to enable TcdA and TcdB to enter the laminar propria and submucosa to induce immune cells to secrete chemokines, proinflammatory cytokines, and mediators which promote proinflammatory and cytotoxic effects [4,13].”
Epidemiology, diagnosis and treatment ofClostridium difficileinfection
Bassetti, M., Villa, G. C. F., Pecori, D., Arzese, A., & Wilcox, M. H. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.135 · Cited by 65
Fuchs, M., Lamm‐Schmidt, V., Sulzer, J., Ponath, F., Jenniches, L., Kirk, J. A., Fagan, R. P., Barquist, L., Vogel, J., & Faber, F. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103579118 · Cited by 69
“The obligate anaerobe, spore-forming Clostridioides difficile (C. difficile) has become the leading cause of antibiotic-associated diarrhea over the past two decades (Rupnik et al., 2009).”
BackgroundRea, M. C., Alemayehu, D., Ross, R. P., & Hill, C. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.058933-0 · Cited by 76
Characteristics of the Clostridium difficile cell envelope and its importance in therapeutics
Kirk, J. A., Banerji, O., & Fagan, R. P. (2017) · Microbial Biotechnology · doi:10.1111/1751-7915.12372 · Cited by 65
“Clostridium difficile is a Gram positive, spore-forming, anaerobic bacterium and is the leading cause of antibiotic-associated nosocomial diarrhoea (Rupnik et al., 2009).”
BackgroundA Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection
Rodrigues, R., Barber, G. E., & Ananthakrishnan, A. N. (2016) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2016.246 · Cited by 73
Protective Effects of Bifidobacterial Strains Against Toxigenic Clostridium difficile
Wei, Y., Yang, F., Wu, Q., Gao, J., Liu, W., Liu, C., Guo, X., Suwal, S., Kou, Y., Zhang, B., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00888 · Cited by 73
“The pseudomembranous colitis and toxic megacolon led by severe infections of C. difficile are potentially fatal (Rupnik et al., 2009).”
BackgroundRussell, G. H., Kaplan, J. L., Youngster, I., Baril‐Dore, M., Schindelar, L., Hohmann, E., & Winter, H. S. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000283 · Cited by 64
Schneeberg, A., Rupnik, M., Neubauer, H., & Seyboldt, C. (2012) · Anaerobe · doi:10.1016/j.anaerobe.2012.08.002 · Cited by 67
Rupnik, M., & Songer, J. G. (2010) · Advances in food and nutrition research · doi:10.1016/s1043-4526(10)60003-4 · Cited by 64
Metadata
- Authors
- Rupnik, M., Wilcox, M. H., & Gerding, D. N.
- Affiliations
- University of Maribor (SI)
- Leeds General Infirmary (GB)
- Loyola University Chicago (US)
- Venue
- Nature Reviews Microbiology
- Published
- 2009-07
- Volume
- 7
- Issue
- 7
- Pages
- 526-536
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- OpenAlex
- W1968953113
- Cited by
- 1,380
- References
- 124
- Citations by year
- 2026: 18 · 2025: 36 · 2024: 49 · 2023: 59 · 2022: 74 · 2021: 72 · 2020: 88 · 2019: 78 · 2018: 109 · 2017: 104 · 2016: 107 · 2015: 107 · 2014: 133 · 2013: 141 · 2012: 93
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- Clostridium difficile infection, nosocomial infections, virulence factors, epidemiology, pathogenesis, community-acquired infections, food-producing animals, antibiotic-associated diarrhea, clinical outcomes, infection prevention and treatment
- MeSH terms
- Animals, Anti-Bacterial Agents, Enterocolitis, Pseudomembranous, Humans, Models, Theoretical, Clostridioides difficile, Virulence Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.